| Disease | IN THIS PHASE I CLINICAL TRIAL 20 PATIENTS WITH CARCINOMA, LYMPHOMA & BLAST CRISIS WERE TREATED WEEKLY. THE PATIENTS RECEIVED A MEDIAN OF 4 WEEKLY DOSES. AT LEAST 2 PATIENTS EACH RECEIVED DOSE LEVELS OF 3.6, 7.2, 12, 18, 32.4, 35, & 43 MG/SQ.M.
4 PATIENTS WITH REFRACTORY HODGKIN'S DISEASE, & 2 PATIENTS WITH REFRACTORY NON-HODGKIN'S LYMPHOMA HAD MINOR RESPONSES LASTING 2-8 WEEKS. THESE PATIENTS RECEIVED DOSES OF 30-43 MG/SQ.M.,& THE AUTHORS RECOMMEND A DOSAGE OF 40 MG/SQ.M.FOR PHASE IITRIAL
NEUROLOGIC, HEMATOLOGIC, & OTHER TOXICITIES WERE SEEN AT DOSES OVER 30MG/SQ.M. TWO CASES OF PERIPHERAL NEUROPATHY, A TRANSIENT LOCALIZED ALLERGIC REACTION & ONE CASE OF TRANSIENT HEPATIC DYSFUNCTION WERE SEEN.
LUEKOPENIA AND NEUTROPENIA WERE SEEN IN 15 OF THE 18 HIGHER DOSE PATIENTS. THERE WAS NO THROMBOCYTOPENIA OR ANEMIA. |